Imaging cellular and molecular processes associated with aneurysm expansion, dissection, and rupture can potentially transform the management of patients with thoracic and abdominal aortic aneurysm. Here, we review recent advances in molecular imaging of aortic aneurysm, focusing on imaging modalities with the greatest potential for clinical translation and application, PET, SPECT, and MRI. Inflammation (e.g., with
INTRODUCTION
Over the past two decades, cardiovascular molecular imaging has moved from a concept to a field on the verge of clinical translation. Potential applications of molecular imaging in cardiovascular medicine continue to expand with some approaches advancing to the clinic, while others are just emerging. The role of molecular imaging as a research tool and its potential contribution to understanding cardiovascular pathophysiology have received considerable attention. Perhaps less emphasis has been placed on the potential of molecular imaging in transforming clinical practice by establishing novel diagnostic and management paradigms, and specific requirements for its clinical application. Seeking to fill this gap, this is the first of a series of reviews on cardiovascular molecular imaging focused on clinical translation and application. To this end, each review starts with a clinical scenario, followed by a discussion of the scope of the problem and diagnostic gaps; pathophysiology; state of the art in molecular imaging; alternative or complementary diagnostics; pitfalls, barriers, and future directions; and potential contribution of molecular imaging to the highlighted case. We hope the format will be of interest to clinicians and scientists and serve as a trigger for dialog to bring the field closer to clinical practice.
CLINICAL SCENARIO
A 65-year-old male with history of dyslipidemia and smoking is referred for routine screening ultrasound for abdominal aortic aneurysm (AAA). Evaluation confirms that the patient is asymptomatic and the physical examination is unremarkable. Screening identifies an infrarenal fusiform AAA with a diameter of 48 mm.
SCOPE OF THE PROBLEM AND DIAGNOSTIC GAPS
The World Health Organization estimates that twelve million deaths were caused worldwide by cardiovascular diseases in 2002. While myocardial infarction and stroke remain the leading causes of cardiovascular mortality, aneurysm rupture and dissection are responsible for a considerable number of cardiovascular deaths. As such, every year, *10,000 deaths are caused by AAA in the US. 1 Arterial aneurysm is defined as a focal dilation of the artery to 1.5 times its normal diameter. 2 In the case of abdominal aorta, by convention, it is considered aneurysmal if its diameter is over 30 mm. 3 The prevalence of AAA is reported to be 4.2% in US veterans aged 50-79 years 4 and 7.2% (of which one-fifth are larger than 45 mm) in Australian men over 65 years of age. 5 Age, gender (male), race (non-black), family history, smoking, and the presence of atherosclerotic disease are risk factors for AAA. 4 Less information is available on the incidence of thoracic aortic aneurysm (TAA). 6 A study in Sweden found the incidence of TAA to be increasing over time, reaching 16.3 and 9.1 per 100,000 per year, respectively, for men and women, in 2002. 7 Most aneurysms are asymptomatic. Rupture and dissection are the main, highly lethal complications of aortic aneurysm. Aneurysm size is the best predictor of its propensity to rupture. As such, rupture occurs in 25-41% of AAA with a diameter [50 mm over a 5-year period. 8 Rapid expansion of an aneurysm is believed to increase its propensity to rupture. Surgical repair is recommended for AAA with a diameter [55 mm, those that increase in size by [10 mm per year, or those that are symptomatic. 9 While open surgery is the mainstay of repair interventions in aortic aneurysm, endovascular aneurysm repair (EVAR) was recently introduced as an alternative to open surgery for aortic aneurysm in a select group of patients. In the US, funding is provided through Medicare for a one-time ultrasound screening for AAA in men [65 years of age who have ever smoked or those of both genders with a family history of AAA. 10 The recommended surveillance interval for AAA depends on its size and expansion rate. For AAA with a diameter of 40 to 54 mm, the surveillance interval is 6 to 12 months. The interval can be longer for smaller aneurysms. 11, 12 While larger aneurysms are more prone to rupture, screening trials have demonstrated that a notable number of ruptures occur in smaller aneurysms which do not meet the criteria for surgical repair. 13, 14 For example, in the Multi-center Aneurysm Screening Study, 23% of ruptures in patients with known aneurysm occurred in those who did not meet the size criteria for repair. Similarly, in the Aneurysm Detection and Management Veterans Affairs Study, there was a rupture rate of 0.6% per year in aneurysms of 40 to 54 mm diameter undergoing biannual surveillance by ultrasonography. A study of small aneurysms in the UK found a rupture rate of 1% per year for aneurysms of 40 to 55 mm in diameter. 15 The risk of rupture is even higher in women, smokers, and those with a history of AAA. Mainly because of the morbidity and mortality associated with surgical repair of aneurysm, none of the randomized studies performed to date support routine surgical repair of smaller aneurysms. 15 Identification of smaller aneurysms that are prone to rupture can tilt the risk-to-benefit balance toward early treatment of the high-risk small aneurysms. At the other end of the spectrum, many patients with aneurysm diameter [55 mm have comorbidities that adversely affect their outcome from invasive interventions. The ability to further risk stratify these patients based on factors other than size would help reassess their risk-to-benefit ratio of therapeutic interventions.
Existing imaging modalities for aortic aneurysm (ultrasonography, CT, and MRI) provide little information beyond anatomy, primarily the dimension of the aneurysm. The challenge is to develop novel approaches to define the risk of expansion, rupture, or dissection more accurately. This would have a major impact on clinical practice (and public health) and can possibly help track the effect of novel therapeutic interventions.
PATHOPHYSIOLOGY
The aorta is a heterogeneous organ, with regional disparities in its cellular origin and structure which are reflected in differences between TAA and AAA pathophysiology. These differences are discussed in depth is several excellent recent reviews. [16] [17] [18] As such, while genetics-based abnormalities of matrix proteins and transforming growth factor (TGF)-b signaling appear to play a predominant role in the development of TAA, AAA is more often associated with atherosclerosis. Nevertheless, both diseases share common features (e.g., inflammation and matrix remodeling) that may be targeted for imaging. Endothelial activation, upregulation of adhesion molecules, and recruitment of leukocytes are early events in vascular pathology and probably play a similar role in AAA development. Proinflammatory chemokines and cytokines are locally produced and accelerate the inflammatory process. This in turn activates proteases, e.g., matrix metalloproteinases (MMPs), which through digestion of matrix proteins facilitate and promote further recruitment of 
MOLECULAR IMAGING
Molecular imaging may target key molecular and cellular players in the pathogenesis of a disease, or biomarkers that, while not direct players in the pathogenesis, potentially provide clinically (or biologically) relevant information on its course. In the case of aortic aneurysm, molecular imaging combined with anatomical imaging and assessment of vessel wall mechanics may offer a comprehensive picture of the disease, including information on its propensity for progression and morbid complications (Table 1) .
Inflammation
An extensive inflammatory infiltrate is present in the media and adventitia of the aneurysm in patients undergoing surgery for AAA symptoms, rapid expansion, or rupture. This infiltrate contains components of both adaptive and innate immunity, including T and B lymphocytes, natural killer cells, and macrophages. The products of these cells, e.g., interferon-c, tumor necrosis factor-a, and interleukin-4, can contribute to aneurysm progression and rupture by promoting inflammation, VSMC death, protease production, and extracellular matrix degradation. 19, 20 As such, inflammatory cell activity is a rational target for imaging aneurysm biology.
Metabolism. 18 F-fluorodeoxy glucose (FDG), a glucose analog which accumulates in cells with high metabolic activity, is often used for PET imaging of inflammation in various clinical settings. 21 The high metabolic activity of activated leukocytes has raised the possibility of using 18 F-FDG PET for detection of vessel wall inflammation in vasculitis, atherosclerosis, and aneurysm. The first reports of 18 F-FDG PET imaging of aortic aneurysm and the possibility of an association between 18 F-FDG uptake and aneurysm expansion, dissection or rupture, date back to more than a decade. 22 Since then, partly as a result of widespread availability and routine use of 18 F-FDG PET in imaging centers, a Table 1 . number of studies have been performed to investigate the potential role of 18 F-FDG PET in evaluation of human aortic diseases. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] As an example, the association between aortic aneurysm and 18 F-FDG uptake in the vessel wall was investigated in a study in 17 patients with AAA (maximal abdominal aortic diameter[3.0 cm) and 17 age-and sex-matched controls selected from a database of patients undergoing 18 F-FDG PET for primary lung cancer. In this study, the maximal standardized uptake value (SUV max ) was significantly higher in the AAA group, but 18 F-FDG uptake in AAA did not correlate with maximal aortic diameter. 26 Several small studies have linked 18 F-FDG uptake in AAA to histologically validated vessel wall inflammation. 30, 34 In a recent study of 18 patients who underwent AAA reparative surgery, 18 F-FDG PET prior to surgery showed no aneurysmal 18 F-FDG uptake in 10 patients and aneurysmal uptake of the tracer in 8 patients. 34 Aortic SUV max to liver SUV max ratio had a modest yet significant correlation with medial and adventitial T and B lymphocyte and macrophage content. While this association between 18 F-FDG uptake and vessel wall inflammation is promising, concluding that 18 F-FDG uptake is a result of vessel wall inflammation would probably require interventional studies aimed at modulating inflammation and demonstrating a corresponding reduction in tracer uptake in the vessel wall. One such intervention could be treatment by statins, which are believed to act also as anti-inflammatory agents. Notably, one small study that looked into this question did not find a difference in AAA 18 F-FDG uptake between patients taking statins and those not taking these drugs. 26 A potential contribution of 18 F-FDG PET imaging to clinical management of aneurysm is to provide reliable information on its propensity for expansion, rupture, or dissection. Demonstration of such a capability is complicated by the average annual change in aneurysm diameter (*2 mm in the case of AAA), 13, 14 which is close to the accuracy of commonly used imaging techniques (ultrasound, CT). Also, the reproducibility of 18 F-FDG uptake in aneurysm and fluctuation of the signal over long periods of follow-up remain to be determined. The predictive value of 18 F-FDG PET imaging was investigated in 34 patients under routine surveillance for non-surgical AAA who were followed for 12 months after an index 18 F-FDG PET study. Surprisingly, in these patients, there was an inverse correlation between average SUV max of transaxial images of aneurysm and future expansion determined by ultrasound (Figure 1) . 28 Similarly, high 18 F-FDG uptake was reported in the so-called inflammatory AAA, which is considered a distinct entity less prone to rupture. 25, 35 These findings contrast with the results of a study of 18 F-FDG PET imaging performed in the acute phase of thoracic aortic dissection, in which SUV mean on images obtained at 50 minutes (but not those obtained at 100 minutes) predicted an unfavorable outcome ( Figure 2) . 23 There are considerable differences in image acquisition, processing, and analysis protocols between various vascular 18 F-FDG PET studies, making it difficult to compare the results. Examples of these variables include the timing of imaging (1 vs 3 hours after tracer administration), fasting status, and quantification methodology (SUV mean vs SUV max vs relative SUV vs target-to-background ratio), highlighting the importance of efforts aimed at standardizing the methodology for vascular 18 F-FDG PET imaging. 36, 37 There is also considerable debate on determinants of 18 F-FDG uptake by inflammatory cells, which appears to be more complicated than initially envisaged. [38] [39] [40] As 18 F-FDG can accumulate in any highly metabolic cell, there is a clinical need for more specific tools to visualize and quantify vessel wall inflammation. Phagocytosis. A potential alternative for imaging vessel wall inflammation is to target the phagocytic activity of macrophages. Superparamagnetic iron oxide (SPIO) and ultrasmall SPIO (USPIO) nanoparticles have shown promise as MR contrast agents for visualizing macrophage phagocytic activity in atherosclerosis and AAA, in small animals and humans. [41] [42] [43] [44] [45] In a recent pilot study, a change in decay of transverse magnetization (appearing as ''signal void'' on T 2 -and T 2 *-weighted MR images) was noted on images acquired before and 36 hours following USPIO administration in patients with aortic aneurysm, raising the possibility that this approach may be used to detect vessel wall inflammation in AAA. 43 The potential of this technique for predicting aneurysm expansion was evaluated in another pilot study in asymptomatic patients with AAA (with a diameter [4.0 cm on ultrasound). 45 The percent change in T 2 * values after administration of USPIO was calculated and a threshold of significance for change (determined based on the variability in T 2 * change in subjects not receiving USPIO) was applied to the dataset. In all patients, there was a non-specific periluminal USPIO signal (possibly due to uptake in thrombus). In a subset of patients, distinct areas of focal USPIO uptake could be seen beyond the periluminal area. These patients had a threefold higher aneurysm growth rate based on two ultrasounds performed 6 months apart, suggesting that the technique may be used to identify patients at higher risk for expansion ( Figure 3) . 45 Importantly, in patients who underwent surgical repair following imaging, iron particles co-localized with CD68? macrophages. 45 Colocalization of USPIO particles with adventitial macrophages has also been noted in a murine model of angiotensin II-induced AAA. 41 Although less sensitive than nuclear imaging for detection of vessel wall biology, MRI has the advantage of providing simultaneous information about aneurysm size, composition, and mechanics. However, iron oxide nanoparticle-based MRI faces a number of pitfalls and major challenges that need to be addressed before its routine clinical application. 46 The basis for signal change by iron oxide particles is complex and depends on their compartment (intracellular/extracellular), among other factors. 47 SPIOs (but not USPIO) clear rapidly from circulation and are not optimal for vascular imaging. 48 Coil position can affect the signal. 48 The methodology for image analysis and signal quantification is based on a number of calculations and quite variable between different studies. 48 The presence of endogenous iron (e.g., in focal loci of hemorrhage or thrombus) can complicate the interpretation of MR images. 49 Another potential limitation is UPSIO uptake in not only macrophages but also endothelial cells and VSMCs. 50 Radiolabeling of nanoparticles is an alternative approach for imaging macrophages based on their phagocytic activity. The feasibility of this approach was investigated in angiotensin II-induced murine aortic aneurysm using 18 F-labeled carbohydrate-coated nanoparticles in conjunction with microPET/CT imaging. 51 On in vivo images obtained 10-12 hours after administration of 18 F-labeled nanoparticles, SUV mean was significantly higher in aneurysmal thoracic aorta compared to the aortae of mice without aneurysm. Splenectomy to deplete macrophages reduced the incidence of aneurysm and led to a significant reduction in aortic tracer uptake. Moreover, in animals imaged at an early time point (1 week), microPET signal (expressed as target-to-background ratio) was significantly higher in mice whose aneurysm went on to expand or rupture. While promising as an alternative to (U)SPIO-based MRI discussed above, the long clearance time of radiolabeled nanoparticles could expose the subjects to high levels of ionizing radiation.
Matrix remodeling
Extracellular matrix degradation and disordered matrix synthesis are key contributors to aortic aneurysm development, expansion, and rupture. Several families of proteases, including cysteine proteases (cathepsins), serine proteases (e.g., neutrophil elastase), and MMPs are expressed at higher than normal levels in aortic aneurysm. 19 In each family, there are several members that exhibit elastase activity and may directly contribute to degradation of elastic laminae, a pathological hallmark of aortic aneurysm.
MMP activation. MMPs and cathepsins have been targeted for molecular imaging of vascular remodeling. [52] [53] [54] [55] [56] [57] [58] [59] However, beyond a single report on fluorescence signal observed ex vivo following administration of a cathepsin B activatable probe in spontaneous murine aortic aneurysm, 58 there is no report of cathepsin imaging in aortic aneurysm. MMPs are a family of zinc-dependent endopeptidases that can degrade extracellular matrix and other proteins. 60 In general, MMPs are produced as inactive zymogens which undergo proteolytic or allosteric activation to expose a catalytic domain. 60 This active site may be targeted for molecular imaging of MMP activation. Inflammatory cells are a major source of MMP production and activation. Several members of MMP family, including MMP-1, -2, -3, -9, -12, and -13, are Journal of Nuclear CardiologyÒ Golestani and Sadeghi 259 Volume 21, Number 2;251-67 Molecular imaging of aortic aneurysm upregulated in aneurysm and their activation contributes to aneurysm progression and rupture. 19 As such, MMPtargeted imaging can potentially provide information on aortic aneurysm propensity for progression and risk of complications. Broad-spectrum MMP inhibitors labeled with gamma-emitters, positron emitters, fluorescent dyes, and MRI contrast agents have been produced and tested for molecular imaging of matrix remodeling (and inflammation) in various settings. 61 Alternatively, it may be possible to develop tracers that detect activation of one or more specific members of MMP family. Given the common structure of MMPs, the development of selective inhibitors for this purpose is a rather challenging task. Nevertheless, as each member of MMP family is a unique protein with distinct biological functions, this approach may be of high value for tracking vascular biology in vivo. Whether imaging a specific member or, alternatively, global activation of MMPs provides the most useful information for risk stratification in aortic aneurysm remains to be empirically determined.
Activatable near infrared fluorescent (NIRF) probes generate a signal upon cleavage of a specific substrate by an enzyme. 62 This leads to signal amplification in vivo. However, the fluorescent nature of the signal limits their use in vascular pathology to imaging small animals or invasive approaches based on intravascular detectors. 63 Also, this technique often requires a long delay between tracer administration and imaging. The potential of this technique was shown in a murine model of TAA using a protease activatable fluorescent imaging agent, MMPsense 680. 64 In vivo fluorescence molecular tomography and ex vivo fluorescence reflectance imaging 20 hours after probe administration showed higher fluorescent signal in animals with thoracic aortic aneurysm. 64 MMPsense 680 contains a peptide substrate, Pro-Leu-Gly-Val-Arg, which can be cleaved with some degree of selectivity by several MMPs, including MMP-1, -2, -7, -8, and -9. 62 A pilot study in rat AAA used the same probe for real-time catheter-based imaging of aortic protease activity. 65 Targeted MRI could be an alternative approach to imaging protease activation in aortic aneurysm. A gadolinium-based MR contrast agent with lM affinities to MMPs (P947 57 ) was evaluated for this purpose in a rat model of elastase-induced AAA. 66 The authors noted a modest mean signal enhancement on T1 spin echo MR images with this agent compared to a non-targeted control agent in aortic segments perfused with elastase. The exact target of P947 remains unclear as there was no ex vivo validation of tracer localization, and this agent has shown similar affinities to other zinc-dependent metalloproteinases including angiotensin-converting enzyme, endothelin-converting enzyme, and aminopeptidases A and N. 67 It remains to be determined whether these levels of signal enhancement change are applicable to imaging in humans.
In contrast with other targeted imaging modalities, nuclear imaging is readily applicable to imaging of human aortic aneurysm. The feasibility of MMP-targeted imaging of aneurysm was shown in a surgical mouse model of carotid aneurysm using RP782, 56 ,68 an 111 In-labeled macrocyclic tracer with nM affinities for several activated MMPs. 69 In this study, specific uptake of the tracer in aneurysm could be seen on microSPECT/ CT images obtained 2 hours after RP782 administration. RP782 uptake in aneurysm paralleled CD68 (macrophage marker) expression and was highest at 4 weeks after aneurysm induction, while the aneurysm diameter continued to increase over an 8-week period. Importantly, MMP tracer uptake on images obtained at an early time point after aneurysm induction correlated with aneurysm size measured at a later time point, indicating that MMP-targeted imaging can predict future aneurysm expansion in this model (Figure 4) . 69 While promising, these observations, including the ability of MMP-targeted imaging to predict aneurysm expansion and rupture, will need to be replicated in additional Golestani and Sadeghi Journal of Nuclear CardiologyÒ Molecular imaging of aortic aneurysm March/April 2014 models of aneurysm before they are ready for clinical translation. Matrix proteins. Collagen and elastin turnover have been targeted for imaging matrix remodeling in aortic aneurysm. CAN-35 is a collagen-binding bacterial protein that preferentially binds to less well-ordered forms of collagen with moderate affinity (500 nM). 70 In a recent study, paramagnetic (gadolinium-based)/fluorescent micellar nanoparticles functionalized with CAN-35 were used to detect and quantify collagen in a murine model of AAA (induced by angiotensin II infusion and TGF-b neutralization). 71 MRI pre-and 32 hours postinjection of the tracer showed higher vessel wall enhancement in AAA compared to normal aorta, and tissue analysis showed co-localization of collagen and fluorescent micelles in AAA. On early imaging, animals with future aneurysm rupture had a lower signal enhancement (suggestive of less fibrotic response), in comparison with animals with stable aneurysm, suggesting that this technique may be used to identify highrisk AAA. The low enhancement pattern on both normal and high-risk arteries can be a limiting factor for clinical translation of this approach.
Another study used a small-molecular-weight gadolinium-based (pro)elastin-specific MRI contrast agent for MR imaging of arterial wall in a mouse model of angiotensin II-induced AAA. 72 While this approach provided useful information on vessel wall morphometry, its usefulness with regards to risk of expansion and rupture remains to be determined. Conceptually, tracers with specificity for mature, organized elastin may be more effective for this purpose. The feasibility of molecular imaging of aorta in large animals using the same MR contrast agent was reported by the same group. 73, 74 Angiogenesis Extensive neovascularization (mostly medial and adventitial) is present in aortic aneurysm and is believed to contribute to aneurysm progression. [75] [76] [77] [78] In general, neovascularization is an integral part of inflammation and in aortic aneurysm the extent of neovascularization correlates with vessel wall inflammation. 77 Furthermore, higher levels of neovascularization are detected at the rupture edge in aortic aneurysm, 79 suggesting that imaging of molecules and processes involved in angiogenesis can potentially depict high-risk aneurysms.
Vascular endothelial growth factor (VEGF) receptors. VEGF and VEGF receptors are key mediators of angiogenesis, and molecular imaging of VEGF receptors using radio-or fluorescent dye-labeled VEGF has shown promising results for imaging angiogenesis in oncology and cardiovascular diseases. [80] [81] [82] [83] Relevant to imaging aneurysm, VEGF receptors are not specific for endothelial cells and can be expressed on inflammatory cells and VSMCs. [84] [85] [86] [87] The feasibility of molecular imaging of VEGF receptors using a Cy 5.5-labeled single chain VEGF (scVEGF) was tested in a mouse model of angiotensin II-induced AAA. In situ and ex vivo fluorescence imaging (only two hours after tracer administration) showed a significantly higher signal in aneurysm compared with remote non-aneurysmal aorta. 88 scVEGF signal intensity correlated with aortic diameter, and while there was evidence of considerable adventitial angiogenesis on tissue analysis, scVEGF fluorescence localized along elastic fibers in the media, 88 questioning whether angiogenesis is indeed the target of scVEGF imaging in this model. Interestingly, in a study on imaging immune-mediated vascular remodeling using the same tracer, scVEGF co-localized with lymphocyte-rich areas of neointima, 89 highlighting the broad expression pattern of VEGF receptors.
avb3 integrin. Integrins are a large family of cell membrane glycoproteins that, among many other functions, mediate cell-cell and cell-matrix interactions. Depending on environmental cues, integrins alternate between low-affinity and high-affinity states. 90, 91 The switch from the low-affinity to high-affinity state, a process called integrin activation, is associated with conformational changes that may be exploited, in conjunction with changes in integrin expression level, for imaging. avb3 integrin is highly expressed (and activated) in proliferating endothelial cells and has been used as a target for imaging angiogenesis. 83 The tripeptide sequence, Arg-Gly-Asp (RGD) which binds to integrins, is the backbone of several tracers used for avb3-targeted imaging. 92, 93 Besides endothelial cells, VSMCs 94 and inflammatory cells express avb3 integrin 95 and thus RGD-based imaging can also be used to detect neointimal hyperplasia 96 and inflammation in the artery. 97 The latter was demonstrated in the aforementioned murine model of carotid aneurysm, in which NC100692, a high-affinity 99m Tc-labeled cyclic RGD peptide was used for in vivo microSPECT/CT imaging of vessel wall inflammation in aneurysm. 97 RGD tracer uptake in aneurysm was attributed, at least in part, to changes in integrin activation state. In another study, an 18 F-labeled RGD-based compound ( 18 F-FPPRGD 2 ) was used for avb3-targeted imaging in murine angiotensin II-induced AAA. 98 MicroPET/CT imaging performed at 21-28 days after angiotensin II infusion showed higher focal tracer uptake in aneurysmal aortae relative to aortae of saline-infused control mice. Immunostaining and autoradiography demonstrated 18 F-FPPRGD 2 localization in areas of macrophage and neovessel abundance within the aneurysm. Furthermore, the number of neovessels and macrophage density, but not vessel diameter, strongly correlated with target-to-background 
ALTERNATIVE OR COMPLEMENTARY DIAGNOSTICS Genetics
Genetic factors play a role in the pathogenesis of TAA that is increasingly reflected in therapeutic decisions. 99, 100 Marfan syndrome and Loeys-Dietz syndrome are two examples of syndromic disorders with aortic involvement, including TAA and dissection, in which earlier surgical treatment is recommended. In addition, the role of TGF-b pathway dysregulation in TAA has raised the possibility of effective medical therapy for these patients. 99 In the case of AAA, the role of genetics is less well established. Fifteen percent of patients with AAA have a positive family history without known connective tissue disorder. A positive family history of AAA doubles the risk for developing AAA. 101, 102 Several genetic loci (e.g., 9p21 region and LRP1) have been linked to both familial and sporadic forms of AAA. 103 However, their contribution to aneurysm expansion or rupture and their impact on management of AAA are not clear.
Circulating biomarkers
Compared with molecular imaging, blood (or urine) biomarkers provide a more global picture of the patient's status. Subtle abnormalities of the rest of the artery(ies) often accompany aortic aneurysm, supporting a potential role for circulating biomarkers in evaluation of aortic aneurysm. Despite many studies, efforts aimed at identification of sensitive and specific biomarkers for aortic aneurysm have yielded limited conclusive results. 104 Circulating biomarkers may be categorized into those associated with the presence of aneurysm and those used for assessment of progression and outcome. 104 In the case of AAA, potential biomarkers include products of extracellular matrix protein turnover, matrix proteases (MMP-9), thrombosis-related proteins, and markers of inflammation (interleukin-6, C-reactive protein). [104] [105] [106] [107] [108] [109] A limitation of these biomarkers is their susceptibility to interference by external factors besides aneurysm biology (e.g., systemic inflammation).
Mechanics
Aneurysm rupture occurs when mechanical stress (the main component of which is systemic blood pressure) exceeds aortic wall tensile strength diminished as a result of matrix remodeling. Patient-specific computational modeling based on aortic geometry (derived from noninvasive imaging), wall stress computation, wall thickness, strength, and compliance, and the presence and extent of intraluminal thrombus may help identify patients who are at risk for aortic aneurysm expansion or rupture. 110, 111 Many of these variables are best measured ex vivo, but can be replaced with more or less accuracy with surrogate in vivo measurements. While a difference in this predicted wall stress is reported between ruptured and non-ruptured AAA, 112, 113 the predictive value (as well as reproducibility) of these measurements for aneurysm expansion, rupture, or dissection remains to be determined. Labor intensity and complexity of these calculations in their current form are major barriers to their routine application in clinical practice. Interestingly, in a small study in 5 patients with thoracic or AAA, regions of high predicted wall stress co-localized with region of high 18 F-FDG uptake on PET images obtained 60 minutes after tracer administration, 33 raising the specter of redundancy (rather than complementarity) of biomechanics assessment and molecular imaging for risk stratification in aortic aneurysm.
PITFALLS, BARRIERS, AND FUTURE DIRECTIONS
Advances in molecular imaging can potentially have a major impact on management of patients with aortic aneurysm. Nuclear imaging techniques, with their high sensitivity and quantitative nature (in conjunction with high resolution anatomic imaging by CT or MRI), can be quite useful for molecular imaging of aneurysm. Like any new field, enthusiasm for novelty is tempered with the necessity of sound methodology and a stepwise approach toward clinical translation. Lack of optimal pre-clinical models of aneurysm, especially in large animals, is a hurdle to be addressed. 114 The nature of the target (size, proximity to blood, etc.) complicates imaging protocol, its reproducibility, and data analysis and may lead to misleading conclusions. As an example, non-specific uptake of tracers is very common in inflammatory diseases such as aortic aneurysm; abdominal aorta in the mouse can be easily mistaken with adjacent structures; and the size of the aorta in small animals and vessel wall thickness in large animals and humans (which are close to spatial resolution of corresponding imaging systems) complicate signal quantification in aneurysm. The variability in image acquisition and analysis methodology, especially for clinical studies, is quite challenging and needs standardization. For any new imaging technique, reproducibility and fluctuation of the signal over time will need to be established. 262 Golestani and Sadeghi Journal of Nuclear CardiologyÒ Molecular imaging of aortic aneurysm March/April 2014
The long-term outcomes of EVAR are not yet welldefined and traditional imaging modalities do not provide sufficient information to predict the need for re-intervention, a gap that may be addressed by molecular imaging. While new techniques for risk stratification of small aneurysms are under development, it is possible that a reduction in procedural complications with EVAR compared to traditional open surgical repair will shift the threshold for intervention toward smaller aneurysms. 115 As we discussed, a number of tracers are under development and evaluation for imaging aortic aneurysm, and conceptually others (e.g., targeted at TGF-b pathway in the case of TAA) may be suitable for this purpose. The economics of novel tracer development entail a large market for a new tracer to be economically viable. One way to address this is to focus on tracers with broad application (e.g., targeting inflammation or remodeling) which can be used in different settings. Existing approved tracers, e.g., 18 F-FDG, need further evaluation for this purpose. In the modern era, introduction of new imaging techniques may require demonstration of not only diagnostic accuracy but also an effect on outcome.
The path forward should include additional basic and pre-clinical studies to better address the biological basis of 18 F-FDG uptake in the vessel wall, as well as adequately powered clinical studies to evaluate 18 F-FDG PET imaging for risk stratification in aneurysm. Imaging and image analysis methodology will need to be standardized. In parallel, the effectiveness and safety profile of existing investigational tracers will need further evaluation in pre-clinical and ultimately clinical studies. Potential pitfalls of existing tracers and progress in our understanding of pathophysiology warrant the quest for new tracers aimed at the same and potentially novel pathways for imaging. Finally, comparative effectiveness and cost analysis research should ascertain the potential contribution of emerging targeted and nontargeted imaging techniques to management of aortic aneurysm.
CASE DISCUSSION
Routine screening is recommended by the ACC/ AHA and the U.S. Preventive Services Task Force in males between 65-75 years of age who have ever smoked. 3, 12 In addition, aortic aneurysms are often discovered incidentally on diagnostic tests performed for other indications. In the case of this patient, current US guidelines recommend follow-up with serial imaging every 6 months, 11 and a referral for open surgery or EVAR for symptoms, rapid growth, or a diameter more than 55 mm. 9 The risk of rupture of *1% per year for aneurysms of 40 to 55 mm in diameter 14 (or possibly higher with a history of smoking 15 ) is less than the risks of surgery (*5% thirty-day mortality for elective and *30% for emergency open surgery
